72.25 USD
+0.67
0.94%
Updated Feb 5, 11:45 AM EST
1 day
0.94%
5 days
0.92%
1 month
-2.06%
3 months
-8.31%
6 months
-12.28%
Year to date
0.71%
1 year
0.29%
5 years
33.01%
10 years
138.69%
 

About: Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Employees: 7,063

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

133% more call options, than puts

Call options by funds: $82.9M | Put options by funds: $35.6M

43% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 67

8% more capital invested

Capital invested by funds: $17.2B [Q2] → $18.5B (+$1.35B) [Q3]

3% more funds holding

Funds holding: 686 [Q2] → 710 (+24) [Q3]

2% less repeat investments, than reductions

Existing positions increased: 260 | Existing positions reduced: 264

1.75% less ownership

Funds ownership: 99.2% [Q2] → 97.44% (-1.75%) [Q3]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$82
13%
upside
Avg. target
$89
23%
upside
High target
$95
31%
upside

8 analyst ratings

positive
38%
neutral
63%
negative
0%
Needham
Mike Matson
60% 1-year accuracy
73 / 122 met price target
25%upside
$90
Hold
Downgraded
3 Feb 2025
Morgan Stanley
Tejas Savant
40% 1-year accuracy
6 / 15 met price target
13%upside
$82
Equal-Weight
Maintained
13 Jan 2025
Jefferies
Tycho Peterson
54% 1-year accuracy
7 / 13 met price target
18%upside
$85
Hold
Initiated
10 Dec 2024
Raymond James
Andrew Cooper
58% 1-year accuracy
7 / 12 met price target
31%upside
$95
Outperform
Maintained
5 Nov 2024
Mizuho
Anthony Petrone
50% 1-year accuracy
17 / 34 met price target
20%upside
$87
Outperform
Maintained
5 Nov 2024

Financial journalist opinion

Based on 21 articles about HOLX published over the past 30 days

Negative
Zacks Investment Research
23 hours ago
Can These 5 MedTech Stocks Hit Earnings Targets This Season?
Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Can These 5 MedTech Stocks Hit Earnings Targets This Season?
Positive
Zacks Investment Research
1 day ago
Hologic (HOLX) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Hologic (HOLX) is a Top-Ranked Value Stock: Should You Buy?
Neutral
Zacks Investment Research
5 days ago
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Countdown to Hologic (HOLX) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Positive
Zacks Investment Research
5 days ago
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Positive
Zacks Investment Research
1 week ago
Hologic (HOLX) Reports Next Week: Wall Street Expects Earnings Growth
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) Reports Next Week: Wall Street Expects Earnings Growth
Positive
Zacks Investment Research
1 week ago
Breast Health Performance Likely to Aid Hologic's Q1 Earnings
In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.
Breast Health Performance Likely to Aid Hologic's Q1 Earnings
Negative
Zacks Investment Research
1 week ago
Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know
Hologic (HOLX) concluded the recent trading session at $71.77, signifying a -1.35% move from its prior day's close.
Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know
Positive
Zacks Investment Research
1 week ago
Hologic's Q1 Earnings Coming Up: How to Play the Stock?
In the first quarter of fiscal 2025, HOLX is expected to have benefited from the strength of its core franchises.
Hologic's Q1 Earnings Coming Up: How to Play the Stock?
Positive
Zacks Investment Research
1 week ago
Why Hologic (HOLX) Outpaced the Stock Market Today
In the closing of the recent trading day, Hologic (HOLX) stood at $71.19, denoting a +1.17% change from the preceding trading day.
Why Hologic (HOLX) Outpaced the Stock Market Today
Neutral
Business Wire
2 weeks ago
New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide
DAVOS, Switzerland--(BUSINESS WIRE)---- $HOLX #HGWHI--New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide.
New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide
Charts implemented using Lightweight Charts™